It is now widely accepted that the putative benefits of cell transplantation are hampered by the high rate of cell death that occurs shortly after the procedure. While this event may not be so relevant to bone marrow-derived cellular grafts whose efficacy seems to depend on cell functionality rather than on the absolute numbers of delivered cells, 1 such is not the case for skeletal myoblasts for which a dose-effect relationship has been demonstrated. 2 It thus appears to be sound to speculate that outcomes of myoblast transplantation could be improved if cell survival was enhanced.
Although postdelivery cell death is a complex phenomenon which involves several intricate factors, three of them have been clearly identified: inflammation due to needle- animals (170), the extended period of follow-up (3 months), a randomised type of design and a combinatorial approach for blindly assessing outcomes. The only concern that one could raise relates to the reliance on a dye-emitted fluorescence for quantifying cell engraftment whereas the more direct identification of a phenotypic marker specific for myoblasts, like fast skeletal myosin, might have yielded more robust data. However, this comment does not question the overall high quality of this study, which has the additional interest of highlighting the possible specific benefits of CSF-1 through its ability to act in both an autocrine manner by stimulating myoblast proliferation and in a paracrine manner by attracting macrophages.
This, in turn, seems to affect the expression pattern of metalloproteases in a way that could beneficially impact on postinfarction left ventricular remodelling.
Once data have been deemed convincing, which is clearly the case for those of this study, the next issue is to figure out how they can be exploited therapeutically. Indeed, myoblast transplantation may now be approaching a crossroad. Clearly however, these effects are not of sufficient magnitude to translate into clinically meaningful improvements in heart failure patient outcomes. From these considerations, two strategic options can be considered.
The "aggressive" option consists of attempting a true regeneration of scarred myocardium by populating it with cells featuring the capacity to functionally integrate into the recipient heart. The increased recognition that adult stem cells have a much more limited plasticity than initially thought has progressively led to the assumption that cells that would best fulfill this requirement were those which recapitulate a cardiomyogenic developmental program. The choice is then fairly limited and the uncertainties regarding the persistence of cardiac stem cells in adulthood 9 lead to the conclusion that appropriately cardiac-specified human embryonic stem cells (ESC) are likely the best candidates for making new myocardial tissue. Despite the ethical and technical issues associated with this cell type, there is now
